King Luther Capital Management Corp Sells 34,470 Shares of Thermo Fisher Scientific Inc. $TMO

King Luther Capital Management Corp reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 733,963 shares of the medical research company’s stock after selling 34,470 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.3% of King Luther Capital Management Corp’s holdings, making the stock its 18th biggest position. King Luther Capital Management Corp owned approximately 0.19% of Thermo Fisher Scientific worth $297,593,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. PFG Advisors bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $260,000. Nuance Investments LLC increased its position in Thermo Fisher Scientific by 1,235.4% during the second quarter. Nuance Investments LLC now owns 87,895 shares of the medical research company’s stock worth $35,638,000 after buying an additional 81,313 shares during the last quarter. Future Fund LLC boosted its stake in shares of Thermo Fisher Scientific by 23.5% during the 2nd quarter. Future Fund LLC now owns 1,875 shares of the medical research company’s stock worth $760,000 after acquiring an additional 357 shares during the period. Midwest Trust Co acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $34,750,000. Finally, Flossbach Von Storch SE lifted its holdings in Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,420 shares of company stock worth $19,980,884 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $572.72 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $215.18 billion, a PE ratio of 33.09, a P/E/G ratio of 3.27 and a beta of 0.82. The firm has a fifty day simple moving average of $518.58 and a 200 day simple moving average of $462.59. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company posted $5.28 EPS. The business’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase program on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Finally, Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.